Sanofi US News

- First industry partner for UCSF's Program for Breakthrough Biomedical Research (PBBR) -

- Collaboration promotes clinical and translational research to address unmet needs of cancer patients in India -

Final 10-year combination chemotherapy adjuvant survival data, studies of investigational agent iniparib to be featured at breast cancer symposium

Vaccine against one of the most common causes of hospital-acquired infection in North America & Europe tested in the U.S.

Investigational Intradermal Influenza Vaccine Induced Comparable Immune Responses to Licensed Fluzone Vaccine with Less Antigen, Smaller Injection Volume

- Focused on translational biomedical research in multiple therapeutic areas such as cancer, diabetes and inflammation -

World’s Largest Influenza Vaccine Producer Awarded $57 Million To Maintain Year-Round Egg Supply for Influenza Pandemic Planning

- Results of the Phase III TROPIC global study published -

Technology of in-vitro Models of the Human Immune System to Provide Competitive Advantage in Vaccine Development

Repeated Doctors Visits, ER Trips, and Admissions to Inpatient/Outpatient Facilities Create High Costs for Managing Patients with a Common, Complex Cardiovascular Disease

-'Diabetes Co-Stars' Offers Information and Support to People Living with Diabetes, Family and Friends -

- Findings Presented at European Association for the Study of Diabetes (EASD) 46th Annual Meeting -

- Phase III Study Results also demonstrated the therapy had acceptable safety profile -

Hundreds of thousands of doses of vaccine and medical supplies also provided

- Funding supports programs to advance personalized medicine -

- 1-vial Taxotere offers simplified preparation -

Early shipments support national goal to increase immunization rates

- Study Findings Presented at American Diabetes Association's 70th Annual Scientific Sessions -

- Study Results Presented at American Diabetes Association's 70th Annual Scientific Sessions -

- First and only therapy to provide significant survival benefit in second-line metastatic hormone-refractory prostate cancer -

- Alliance formed to advance cutting-edge research and foster collaboration between academia and industry -

- Sanofi-aventis Supports Consortium's Activities to Fund Promising Early-Stage Life Sciences Companies -

The licensed technology was developed by the NMRC with the help of the University of Colorado

Interactive Exhibit Unveiled at New Jersey's Liberty Science Center as it Embarks on Three-Year, 12-City Tour

Chattem Becomes the U.S. Consumer Healthcare Platform for sanofi-aventis

- Results observed in patients treated with cabazitaxel plus prednisone whose disease progressed despite prior docetaxel-based chemotherapy -

The Coalition to Prevent DVT Sends Awareness into Motion with an Educational Program Focusing on Preventative Care Through Movement

New Data Published by Journal of American Academy of Dermatology Demonstrated Sustained Efficacy Up to 25 Months